Targovax ASA (TRVX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Targovax ASA (TRVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8239
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG0, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline product for solid tumor indications. It also provides TG02, TG03, ONCOS-402, ONCOS-802 and ONCOS-902 for other cancer indications. Targovax develops immunotherapies based on treatment approaches harnessing the patient’s immune system to target cancer, which include a virus-based immunotherapy platform based on engineered oncolytic viruses for solid tumors; and a peptide-based immunotherapy platform for RAS-mutated cancers. The company operates through its offices in Norway and Finland. Targovax is headquartered in Oslo, Norway.

Targovax ASA (TRVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Targovax ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Targovax ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Targovax ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Targovax Raises US$1.3 Million In Venture Financing 11
Targovax Raises US$2.2 Million In Series A Financing 12
Targovax Raises Additional US$1 Million In Venture Financing 13
Partnerships 14
Targovax Enters into Agreement with Sotio 14
Ludwig Institute for Cancer Research and Cancer Research Institute Partner with Targovax 15
Merger 16
Oncos Therapeutics Completes Merger with Targovax 16
Equity Offering 17
Targovax Raises USD0.8 Million in Rights Offering of Shares 17
Targovax Raises USD23.6 Million in Private Placement of Shares 18
Targovax Raises USD0.5 Million in IPO 20
Targovax Raises USD13.3 Million in Private Placement of Shares 21
Targovax Raises USD26 Million in Private Placement of Shares 22
Targovax Raises USD11.6 Million through Shares Issue 24
Targovax ASA – Key Competitors 25
Targovax ASA – Key Employees 26
Targovax ASA – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Feb 15, 2018: Targovax: Fourth quarter and full year 2017 results 28
Apr 25, 2017: Targovax:First quarter 2017 results 30
Feb 16, 2017: Targovax: Fourth quarter and full year 2016 results 31
Corporate Communications 33
Sep 13, 2018: Targovax strengthens management team with the appointment of Torbjorn Furuseth as CFO; Erik Digman Wiklund to become CBO 33
Apr 12, 2018: Targovax strengthens Board of Directors with the appointment of Catherine Wheeler 34
Jan 08, 2018: Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer 35
Nov 30, 2017: Targovax: New Member of the Board of Directors – Nov. 30, 2017 36
Mar 22, 2017: Targovax: The board of directors of Oslo Stock Exchange approves transfer of Targovax to the main list 37
Jan 05, 2017: Targovax announces appointment of Erik Digman Wiklund as CFO 38
Other Significant Developments 39
Aug 23, 2018: Targovax: Second quarter and first half year 2018 results 39
Jun 11, 2018: Targovax Strengthens Focus on ONCOS Oncolytic Virus Development Program 40
May 03, 2018: Targovax: First quarter 2018 results 41
Nov 02, 2017: Targovax: Third quarter 2017 results 42
Aug 24, 2017: Targovax: Second quarter and first half 2017 results 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Targovax ASA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Targovax ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Targovax ASA, Deals By Therapy Area, 2012 to YTD 2018 9
Targovax ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Targovax Raises US$1.3 Million In Venture Financing 11
Targovax Raises US$2.2 Million In Series A Financing 12
Targovax Raises Additional US$1 Million In Venture Financing 13
Targovax Enters into Agreement with Sotio 14
Ludwig Institute for Cancer Research and Cancer Research Institute Partner with Targovax 15
Oncos Therapeutics Completes Merger with Targovax 16
Targovax Raises USD0.8 Million in Rights Offering of Shares 17
Targovax Raises USD23.6 Million in Private Placement of Shares 18
Targovax Raises USD0.5 Million in IPO 20
Targovax Raises USD13.3 Million in Private Placement of Shares 21
Targovax Raises USD26 Million in Private Placement of Shares 22
Targovax Raises USD11.6 Million through Shares Issue 24
Targovax ASA, Key Competitors 25
Targovax ASA, Key Employees 26
Targovax ASA, Other Locations 27
Targovax ASA, Subsidiaries 27

List of Figures
Targovax ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Targovax ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Targovax ASA (TRVX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Maxeda B.V.:戦略・SWOT・企業財務分析
    Maxeda B.V. - Strategy, SWOT and Corporate Finance Report Summary Maxeda B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Nabriva Therapeutics plc (NBRV):企業の財務・戦略的SWOT分析
    Summary Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company offers product candidate such as Xenleta (lefamulin), CONTEPO (fosfomycin), being developed in both intravenous and oral formulations for th …
  • Damen Shipyards Group:企業の戦略・SWOT・財務情報
    Damen Shipyards Group - Strategy, SWOT and Corporate Finance Report Summary Damen Shipyards Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bank Muscat:企業の戦略・SWOT・財務分析
    Bank Muscat - Strategy, SWOT and Corporate Finance Report Summary Bank Muscat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • The Bidvest Group Ltd:企業のM&A・事業提携・投資動向
    The Bidvest Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Bidvest Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Genomic Health Inc (GHDX):医療機器:M&Aディール及び事業提携情報
    Summary Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer …
  • GridPoint, Inc.-エネルギー分野:企業M&A・提携分析
    Summary GridPoint, Inc. (Gridpoint), a subsidiary of Twenty First Century Utilities LLC, is a provider of data-driven energy management systems. The company offers a wide range of energy management hardware including control, equipment-level sub-metering and advanced monitoring devices such as contr …
  • Casio Computer Co Ltd (6952):企業の財務・戦略的SWOT分析
    Casio Computer Co Ltd (6952) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Long Run Exploration Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Long Run Exploration Ltd (Long Run), formerly WestFire Energy Ltd, a subsidiary of Calgary Sinoenergy Investment Corp, is an oil and gas company that offers development and exploration of light oil. The company grows crude oil volumes within its diversified portfolio properties. Its oil expl …
  • IntriCon Corp (IIN):企業の財務・戦略的SWOT分析
    Summary IntriCon Corp (IntriCon) is a designer, developer and manufacturer of miniature and micro-miniature body-worn medical and electronics products. The company’s products comprise glucose monitoring, medical coils, cardiac monitoring, amplifiers, systems, plastic medical molding, support product …
  • The Saudi British Bank (1060):企業の財務・戦略的SWOT分析
    The Saudi British Bank (1060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Dermalogica, Inc.:企業の戦略・SWOT・財務情報
    Dermalogica, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dermalogica, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • SciBase AB (SCIB)-医療機器分野:企業M&A・提携分析
    Summary SciBase AB (SciBase) is a medical technology company that offers non-invasive detection and monitoring of skin tissue alterations. The company has developed point of care device for the accurate detection of malignant melanoma. It offers products which include electrical impedance spectrosco …
  • Apollo Endosurgery Inc (APEN):製薬・医療:M&Aディール及び事業提携情報
    Summary Apollo Endosurgery Inc (Apollo Endo), formerly Lpath Inc, is a medical technology company that designs, develops and commercializes medical devices used for the treatment of obesity. The company’s product portfolio comprises endo-bariatric products such as Orbera Intragastric Balloon System …
  • ESSA Pharma Inc (EPI):企業の財務・戦略的SWOT分析
    Summary Essa Pharma Inc (Essa Pharma) is a drug developer that offers oncology therapeutics. The company develops EPI-506, disrupts androgen receptor transcriptional activity through selectively blocking the N-terminal domain of the AR. It also conducts research on prostate cancer and the androgen r …
  • Regal Petroleum plc (RPT):企業の財務・戦略的SWOT分析
    Summary Regal Petroleum Plc (Regal), a subsidiary of Energees Investments Ltd, is an oil and gas company that conducts reviews on oil and gas projects. The company operates two gas and condensate fields such as Mekhediviska - Golotovschinska and Svyrydivske located in Dneipner-Donets basin in the no …
  • PT Bio Farma:製薬・医療:M&Aディール及び事業提携情報
    Summary PT Bio Farma (Bio Farma) is a manufacturer and supplier of vaccines, sera, and biological and diagnostics products. The company offers products such as DTP-hep B vaccine, DTP vaccine, DT vaccine, TT vaccine, polio vaccine, measles vaccine and BCG vaccine. It also offers biott vaccine for the …
  • BDO International Ltd:企業の戦略的SWOT分析
    BDO International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • TVS Motor Co Ltd:戦略・SWOT・企業財務分析
    TVS Motor Co Ltd - Strategy, SWOT and Corporate Finance Report Summary TVS Motor Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Telekom Slovenije, d.d. (TLSG):企業の財務・戦略的SWOT分析
    Telekom Slovenije, d.d. (TLSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆